{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T08:50:56Z","timestamp":1791363056106,"version":"4.3.1"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,9]],"date-time":"2025-07-09T00:00:00Z","timestamp":1752019200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013362","name":"Cancer Research Foundation Switzerland","doi-asserted-by":"publisher","award":["KFS-6223\\u201308\\u20132024"],"award-info":[{"award-number":["KFS-6223\\u201308\\u20132024"]}],"id":[{"id":"10.13039\/501100013362","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.ejca.2025.115601","type":"journal-article","created":{"date-parts":[[2025,7,5]],"date-time":"2025-07-05T02:50:57Z","timestamp":1751683857000},"page":"115601","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Translating spared and delayed tumor-draining lymph node irradiation into clinical practice: Current clinical trials and future directions"],"prefix":"10.1016","volume":"226","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-4412-1450","authenticated-orcid":false,"given":"Sabrina","family":"Reichl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Pruschy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-3839-1277","authenticated-orcid":false,"given":"Marvin","family":"Kreuzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5261-6446","authenticated-orcid":false,"given":"Panagiotis","family":"Balermpas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1657-4650","authenticated-orcid":false,"given":"Irma","family":"Telarovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2025.115601_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2022.188704","article-title":"Tumor draining lymph nodes, immune response, and radiotherapy: towards a revisal of therapeutic principles","volume":"1877","author":"Koukourakis","year":"2022","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"10.1016\/j.ejca.2025.115601_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","article-title":"Oncology meets immunology: the cancer-immunity cycle","volume":"39","author":"Chen","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/j.ejca.2025.115601_bib3","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1016\/j.immuni.2023.09.011","article-title":"The cancer-immunity cycle: Indication, genotype, and immunotype","volume":"56","author":"Mellman","year":"2023","journal-title":"Immunity"},{"key":"10.1016\/j.ejca.2025.115601_bib4","article-title":"Synergizing radiotherapy and immunotherapy: Current challenges and strategies for optimization","volume":"36","author":"Rajeev-Kumar","year":"2023","journal-title":"Neoplasia N Y N"},{"key":"10.1016\/j.ejca.2025.115601_bib5","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.trecan.2021.10.003","article-title":"Radiotherapy and immunotherapy: open questions and future strategies","volume":"8","author":"Pointer","year":"2022","journal-title":"Trends Cancer"},{"key":"10.1016\/j.ejca.2025.115601_bib6","doi-asserted-by":"crossref","first-page":"5058","DOI":"10.1158\/1078-0432.CCR-17-3427","article-title":"Elective nodal irradiation attenuates the combinatorial efficacy of stereotactic radiation therapy and immunotherapy","volume":"24","author":"Marciscano","year":"2018","journal-title":"Clin Cancer Res J Am Assoc Cancer Res"},{"key":"10.1016\/j.ejca.2025.115601_bib7","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nri.2017.108","article-title":"The diverse functions of the PD1 inhibitory pathway","volume":"18","author":"Sharpe","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.ejca.2025.115601_bib8","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0157164","article-title":"Optimizing timing of immunotherapy improves control of tumors by hypofractionated radiation therapy","volume":"11","author":"Young","year":"2016","journal-title":"PloS One"},{"key":"10.1016\/j.ejca.2025.115601_bib9","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abg0117","article-title":"Sequence of \u03b1PD-1 relative to local tumor irradiation determines the induction of abscopal antitumor immune responses","volume":"6","author":"Wei","year":"2021","journal-title":"Sci Immunol"},{"key":"10.1016\/j.ejca.2025.115601_bib10","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000867","article-title":"Tumor-draining lymph node is important for a robust abscopal effect stimulated by radiotherapy","volume":"8","author":"Buchwald","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ejca.2025.115601_bib11","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.1158\/0008-5472.CAN-09-2982","article-title":"Local radiation therapy inhibits tumor growth through the generation of tumor-specific CTL: its potentiation by combination with Th1 cell therapy","volume":"70","author":"Takeshima","year":"2010","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2025.115601_bib12","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.124507","article-title":"Tumor-draining lymph nodes are pivotal in PD-1\/PD-L1 checkpoint therapy","volume":"3","author":"Fransen","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.ejca.2025.115601_bib13","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1158\/2326-6066.CIR-14-0196","article-title":"Stereotactic radiation therapy augments antigen-specific PD-1-mediated antitumor immune responses via cross-presentation of tumor antigen","volume":"3","author":"Sharabi","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.ejca.2025.115601_bib14","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.ccell.2020.09.001","article-title":"The PD-1\/PD-L1-checkpoint restrains T cell immunity in tumor-draining lymph nodes","volume":"38","author":"Dammeijer","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejca.2025.115601_bib15","first-page":"121","article-title":"Radiation sensitivity of human and murine peripheral blood lymphocytes, stem and progenitor cells","volume":"1846","author":"Heylmann","year":"2014","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.ejca.2025.115601_bib16","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19113574","article-title":"Clinically relevant radiation exposure differentially impacts forms of cell death in human cells of the innate and adaptive immune system","volume":"19","author":"Falcke","year":"2018","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ejca.2025.115601_bib17","doi-asserted-by":"crossref","first-page":"5500","DOI":"10.1038\/s41467-024-49873-y","article-title":"Delayed tumor-draining lymph node irradiation preserves the efficacy of combined radiotherapy and immune checkpoint blockade in models of metastatic disease","volume":"15","author":"Telarovic","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.ejca.2025.115601_bib18","unstructured":"TDLN-sparing R.T. Plus Immunotherapy and Chemotherapy in Locally Advanced ESCC. ClinicalTrialsGov n.d. \u3008https:\/\/clinicaltrials.gov\/study\/NCT06676449\u3009 (accessed January 20, 2025)."},{"key":"10.1016\/j.ejca.2025.115601_bib19","unstructured":"Node-sparing Short-Course Radiation combined with CAPOX and Tislelizumab for MSS Rectal Cancer (mRCAT-III). ClinicalTrialsGov n.d. \u3008https:\/\/clinicaltrials.gov\/study\/NCT06507371\u3009 (accessed January 20, 2025)."},{"key":"10.1016\/j.ejca.2025.115601_bib20","doi-asserted-by":"crossref","first-page":"3355","DOI":"10.1200\/JCO.24.01160","article-title":"Management of locally advanced rectal cancer: ASCO Guideline","volume":"42","author":"Scott","year":"2024","journal-title":"J Clin Oncol J Am Soc Clin Oncol"},{"key":"10.1016\/j.ejca.2025.115601_bib21","doi-asserted-by":"crossref","first-page":"3724","DOI":"10.1200\/JCO.23.00903","article-title":"Patient-reported outcomes during and after treatment for locally advanced rectal cancer in the PROSPECT Trial (Alliance N1048)","volume":"41","author":"Basch","year":"2023","journal-title":"J Clin Oncol J Am Soc Clin Oncol"},{"key":"10.1016\/j.ejca.2025.115601_bib22","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1056\/NEJMoa2201445","article-title":"PD-1 blockade in mismatch repair-deficient, locally advanced rectal cancer","volume":"386","author":"Cercek","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2025.115601_bib23","unstructured":"Node-sparing Radiotherapy Combined with Total Neoadjuvant CAPOX and Sintilimab for MSS Middle and Low Rectal Cancer (CASINOs). ClinicalTrialsGov n.d. \u3008https:\/\/clinicaltrials.gov\/study\/NCT06204094\u3009 (accessed January 20, 2025)."},{"key":"10.1016\/j.ejca.2025.115601_bib24","unstructured":"Node-sparing Short-Course Radiation with CAPOX and Sintilimab for MSS Locally Advanced Colon Cancer: a Randomized, Prospective, Multicenter Study (mRCAT-C). ClinicalTrialsGov n.d. \u3008https:\/\/clinicaltrials.gov\/study\/NCT06594692\u3009 (accessed January 20, 2025)."},{"key":"10.1016\/j.ejca.2025.115601_bib25","unstructured":"Nodal Radiation Therapy for Sentinel Lymph Node Positive Melanoma (MelPORT). ClinicalTrialsGov n.d. \u3008https:\/\/clinicaltrials.gov\/study\/NCT04594187\u3009 (accessed January 20, 2025)."},{"key":"10.1016\/j.ejca.2025.115601_bib26","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11133880","article-title":"Does it really pay-off? Comparison of lymphadenectomy versus observational approach in skin melanoma with positive sentinel node biopsy: systematic review and meta-analysis","volume":"11","author":"Richter","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.ejca.2025.115601_bib27","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1056\/NEJMoa2402604","article-title":"Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma","volume":"391","author":"Blank","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2025.115601_bib28","first-page":"1237","article-title":"Preclinical study and phase II trial of adapting low-dose radiotherapy to immunotherapy in small cell lung cancer","volume":"5","author":"Wang","year":"2024","journal-title":"Med N Y N"},{"key":"10.1016\/j.ejca.2025.115601_bib29","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S1470-2045(24)00573-4","article-title":"Primary lung tumour stereotactic body radiotherapy followed by concurrent mediastinal chemoradiotherapy and adjuvant immunotherapy for locally advanced non-small-cell lung cancer: a multicentre, single-arm, phase 2 trial","volume":"26","author":"Heinzerling","year":"2025","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2025.115601_bib30","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/1748-717X-8-103","article-title":"Selective use of postoperative neck radiotherapy in oral cavity and oropharynx cancer: a prospective clinical study","volume":"8","author":"Mart\u00ednez Carrillo","year":"2013","journal-title":"Radiat Oncol Lond Engl"},{"key":"10.1016\/j.ejca.2025.115601_bib31","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1447123","article-title":"De-intensification of postoperative radiotherapy in head and neck cancer irrespective of human papillomavirus status-results of a prospective multicenter phase II trial (DIREKHT Trial)","volume":"14","author":"Haderlein","year":"2024","journal-title":"Front Oncol"},{"key":"10.1016\/j.ejca.2025.115601_bib32","unstructured":"De-Intensification of Postoperative Radiotherapy in Patients with Squamous Cell Carcinoma of the Head and Neck (DIREKHT2). ClinicalTrialsGov n.d. \u3008https:\/\/clinicaltrials.gov\/study\/NCT06030440\u3009 (accessed June 16, 2025)."},{"key":"10.1016\/j.ejca.2025.115601_bib33","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1016\/j.ijrobp.2024.08.022","article-title":"A Phase II Single Arm Trial of Elective Volume Adjusted De-Escalation Radiotherapy (EVADER) in Patients with Low-risk HPV-related Oropharyngeal Squamous Cell Carcinoma","volume":"120","author":"Bratman","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ejca.2025.115601_bib34","unstructured":"Personalized Volume-deescalated Elective Nodal Irradiation in Oropharyngeal Head and Neck Squamous Cell Carcinoma (DeEscO). ClinicalTrialsGov n.d. \u3008https:\/\/clinicaltrials.gov\/study\/NCT06563362\u3009 (accessed March 18, 2025)."},{"key":"10.1016\/j.ejca.2025.115601_bib35","doi-asserted-by":"crossref","first-page":"S615","DOI":"10.1016\/j.annonc.2024.08.913","article-title":"852MO REWRITE\u2013GORTEC 2018-02: Radiotherapy-durvalumab without prophylactic neck irradiation in squamous cell carcinoma of the head and neck","volume":"35","author":"Castelli","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2025.115601_bib36","doi-asserted-by":"crossref","DOI":"10.1200\/JCO-24-01580","article-title":"Randomized Phase II study of concurrent versus sequential pembrolizumab in combination with chemoradiation in locally advanced head and neck cancer","author":"Zandberg","year":"2025","journal-title":"J Clin Oncol J Am Soc Clin Oncol"},{"key":"10.1016\/j.ejca.2025.115601_bib37","unstructured":"LySAIRI: towards an innovative radiotherapy that facilitates immune sparing to improve overall clinical efficacy. Gustave Roussy n.d. \u3008https:\/\/www.gustaveroussy.fr\/en\/lysairi-towards-innovative-radiotherapy-facilitates-immune-sparing-improve-overall-clinical-efficacy\u3009 (accessed March 18, 2025)."},{"key":"10.1016\/j.ejca.2025.115601_bib38","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1158\/1078-0432.CCR-23-3632","article-title":"Translational frontiers and clinical opportunities of immunologically fitted radiotherapy","volume":"30","author":"Morel","year":"2024","journal-title":"Clin Cancer Res J Am Assoc Cancer Res"},{"key":"10.1016\/j.ejca.2025.115601_bib39","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1056\/NEJMoa1809697","article-title":"Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC","volume":"379","author":"Antonia","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2025.115601_bib40","doi-asserted-by":"crossref","unstructured":"Bradley J.D., Nishio M., Okamoto I., Newton M.D., Trani L., Shire N.J., et al. PACIFIC-2: Phase 3 study of concurrent durvalumab and platinum-based chemoradiotherapy in patients with unresectable, stage III NSCLC. 2019.","DOI":"10.1200\/JCO.2019.37.15_suppl.TPS8573"},{"key":"10.1016\/j.ejca.2025.115601_bib41","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/S1470-2045(24)00100-1","article-title":"Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial","volume":"25","author":"Machiels","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2025.115601_bib42","unstructured":"Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689). ClinicalTrialsGov n.d. \u3008https:\/\/clinicaltrials.gov\/study\/NCT03765918\u3009 (accessed March 18, 2025)."},{"key":"10.1016\/j.ejca.2025.115601_bib43","unstructured":"Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) Met Primary Endpoint of Event-Free Survival (EFS) as Perioperative Treatment Regimen in Patients With Resected, Locally Advanced Head and Neck Squamous Cell Carcinoma MerckCom n.d. \u3008https:\/\/www.merck.com\/news\/mercks-keytruda-pembrolizumab-met-primary-endpoint-of-event-free-survival-efs-as-perioperative-treatment-regimen-in-patients-with-resected-locally-advanced-head-and-neck-squamous-c\/\u3009 (accessed March 18, 2025)."},{"key":"10.1016\/j.ejca.2025.115601_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2021.103497","article-title":"The impact of pelvic nodal radiotherapy on hematologic toxicity: a systematic review with focus on leukopenia, lymphopenia and future perspectives in prostate cancer treatment","volume":"168","author":"Iorio","year":"2021","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.ejca.2025.115601_bib45","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1007\/s00262-024-03810-6","article-title":"A comprehensive and longitudinal evaluation of the different populations of lymphoid and myeloid cells in the peripheral blood of patients treated with chemoradiotherapy for head and neck cancer","volume":"73","author":"von der Gr\u00fcn","year":"2024","journal-title":"Cancer Immunol Immunother CII"},{"key":"10.1016\/j.ejca.2025.115601_bib46","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001429","article-title":"Radiomics to predict outcomes and abscopal response of patients with cancer treated with immunotherapy combined with radiotherapy using a validated signature of CD8 cells","volume":"8","author":"Sun","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ejca.2025.115601_bib47","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001845","article-title":"Prospective development and validation of a liquid immune profile-based signature (LIPS) to predict response of patients with recurrent\/metastatic cancer to immune checkpoint inhibitors","volume":"9","author":"Zhou","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ejca.2025.115601_bib48","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1451035","article-title":"Defining intra-tumoral and systemic immune biomarkers for locally advanced head-and-neck cancer - detailed protocol of a prospective, observatory multicenter trial (ImmunBioKHT) and first results of the immunophenotyping of the patients\u2019 peripheral blood","volume":"14","author":"Donaubauer","year":"2024","journal-title":"Front Oncol"},{"key":"10.1016\/j.ejca.2025.115601_bib49","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.cytogfr.2013.03.001","article-title":"A myriad of functions and complex regulation of the CCR7\/CCL19\/CCL21 chemokine axis in the adaptive immune system","volume":"24","author":"Comerford","year":"2013","journal-title":"Cytokine Growth Factor Rev"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804925003831?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804925003831?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T08:05:13Z","timestamp":1791360313000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804925003831"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":49,"alternative-id":["S0959804925003831"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2025.115601","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Translating spared and delayed tumor-draining lymph node irradiation into clinical practice: Current clinical trials and future directions","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2025.115601","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"115601"}}